Clinical Trial: PCV24 in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months

U.S., Jan. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07333352) titled 'PCV24 in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months' on Dec. 01, 2025.

Brief Summary: The Phase II clinical trial of the 24-valent pneumococcal polysaccharide conjugate vaccine (PCV24), jointly conducted by Shanghai Reinvax Biotechnology Co., Ltd, Shanghai Microdom Biotech Co., Ltd and Changchun Reinovax Biologics Co.,Ltd, will be carried out in infants and young children aged 2 months (minimum 6 weeks) to 71 months. The purpose of this study is to evaluate the immunogenicity and safety of the 24-valent pneumococcal polysaccharide conjugate vaccine in infants and young children aged 2 months (minimum 6 w...